Carnegie acted as financial adviser and joint bookrunner in the directed new share issue of 1.1 million new shares at a subscription price of SEK 93 per share. Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. June 2018.
Healthcare
Directed new share issue in Camurus AB (SE) — SEK 102 million
June 2018